Skip to main content

Hemostemix Inc(HEM-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.065
Day High0.070
Open:0.070
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newsfile
Upcoming Meeting Dates - April 20, 2026
Newsfile
Hemostemix Leadership Attending Abundance360 Summit
Newsfile
Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships
Newsfile
Hemostemix Receives FDA Support for Its Basket Protocol Approach
Newsfile
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
Newsfile
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
Newsfile
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
Newsfile
Hemostemix Grants Stock Options
Newsfile
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
Newsfile
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations
Newsfile
Hemostemix to Attend DFCon San Antonio and Closed its Private Placement
Newsfile
Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two
Newsfile
Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia
Newsfile
Hemostemix Closes CDN$280,594 Private Placement
Newsfile
Hemostemix to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida
Newsfile
Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway
Newsfile
Hemostemix Closes Private Placement of $461,230
Newsfile
Hemostemix's Boots on the Ground in Florida October Update
Newsfile
Hemostemix Announces Its Webinar for Florida Vascular Surgeons: Autologous Stem Cell Therapy for CLTI
Newsfile
Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42
Newsfile
Hemostemix Adds the Treatment of Refractory Angina to Its Phase 1 Basket Protocol
Newsfile
Hemostemix Files for Ethics Approval of its Study of Vascular Dementia
INK Research
CEO buying at Hemostemix (HEM)
Company Chart of HEM
Newsfile
Hemostemix's Insider Lead Order of $330,000 Private Placement
Newsfile
Hemostemix Files FDA Submission for Basket Protocol (Filing 1517) to Advance ACP-01 (VesCell(TM)) Across Multiple Ischemic and Vascular Indications Simultaneously
GlobeNewswire
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
Newsfile
Hemostemix to Present at Life Science Investor Forum
Newsfile
Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina
GlobeNewswire
Life Science Virtual Investor Forum Agenda Announced for September 18th
Newsfile
Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share
Newsfile
Hemostemix Announces Private Placement
Newsfile
Hemostemix Launches Enhanced HubSpot-Powered Websites to Support Global Marketing & Sales of ACP-01 for No-Option Patients

Profile

Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.